OncLive TV

Michelle M. Boisen, MD, discusses the scoring system for optimal debulking in ovarian cancer.

Andre Goy, MD, MS, discusses the paradigm shift in the treatment of patients with mantle cell lymphoma that has occurred over the past decade.

Melissa K. Accordino, MD, MS, discusses the findings of the PEARL trial in hormone receptor-positive, HER2-negative metastatic breast cancer.

Farrukh Awan, MD, discusses questions regarding combination therapies in chronic lymphocytic leukemia.

Casey M. Cosgrove, MD, discusses the utilization of PARP inhibition in ovarian cancer.

Himisha Beltran, MD, discusses the utility of liquid biopsies versus tissues biopsies in castration-resistant neuroendocrine prostate cancer.

John L. Marshall, MD, discusses the push toward precision medicine in colorectal cancer.

William K. Oh, MD, discusses the role of radiopharmaceuticals in metastatic castration-resistant prostate cancer.

Eileen O'Reilly, MD, discusses germline testing in pancreatic cancer.

Petros Grivas, MD, PhD, discusses potential combination regimens with cabazitaxel in prostate cancer.

Gregory A. Otterson, MD, discusses when to start treatment with immunotherapy in patients with non–small cell lung cancer.

Alexey V. Danilov, MD, PhD, discusses the potential for combining venetoclax with novel BTK inhibitors in chronic lymphocytic leukemia.

Sara M. Tolaney, MD, MPH, discusses remaining sequencing questions in breast cancer.

Robert E. Merritt, MD, FACS, discusses the long-term oncologic outcomes of robotic lobectomy versus video-assisted thoracoscopic surgery and open thoracotomy in early-stage non-small-cell lung cancer.

Jorge E. Cortes, MD, discusses the safety profile of ruxolitinib in patients with myeloproliferative neoplasms.

Neelima Denduluri, MD, shares treatment approaches in patients with early-stage hormone receptor-positive, HER2-negative breast cancer.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses ongoing research in mantle cell lymphoma (MCL).

Paul M. Barr, MD, Wilmot Cancer Institute, University of Rochester, discusses the results of a phase I/II study evaluating the combination of umbralisib, ublituximab, and venetoclax (Venclexta) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

Lan G. Coffman, MD, PhD, assistant professor at the University of Pittsburgh Medical (UPMC) Center Hillman Cancer Center, discusses safety concerns with PARP inhibitors in ovarian cancer.

Michelle M. Boisen, MD, discusses criteria for selecting patients with ovarian cancer for upfront surgery versus neoadjuvant chemotherapy.

Richard T. Penson, MD, MRCP, associate professor of medicine, Harvard Medical School, and clinical director of Medical Gynecologic Oncology, in the Department of Medicine, Massachusetts General Hospital, discusses re-challenging with PARP inhibition in patients with ovarian cancer.

Katherine D. Crew, MD, MS, director of Clinical Breast Cancer Prevention Program, Columbia University Irving Medical Center, and director of DataBase Shared Resource at Herbert Irving Comprehensive Cancer Center, Columbia University, discusses updated data with margetuximab in HER2-positive breast cancer.

Aaron Goodman, MD, hematologist/oncologist and assistant professor of medicine at the University of California, San Diego, discusses the importance of the phase III ECHELON-2 data in peripheral T-cell lymphoma (PTCL).

Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, previews discussion topics for the upcoming webinar hosted by OncLive on the novel coronavirus 2019 (COVID-19).

Benjamin P. Levy, MD, discusses emerging biomarkers and their respective therapies in lung cancer.

Robb S. Friedman, MD, discusses the mechanism of action of selinexor in multiple myeloma.

Wolfgang Fendler, MD, discusses the rationale for creating the 68Ga-PSMA-11 PET in prostate cancer.

Tannaz Armaghany, MD, discusses sorafenib versus lenvatinib as first-line therapy for patients with hepatocellular carcinoma.

Diane M. Simeone, MD, explains which patients with pancreatic cancer should receive neoadjuvant therapy.

Bruce G. Raphael, MD, discusses the risk of tumor lysis syndrome in chronic lymphocytic leukemia.